IBI-3014
- Generic Name
- IBI-3014
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Unresectable Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT06974812
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath